Among the grade 3 or higher AE, the quadruple therapy group exhibited higher incidences of elevated total bilirubin (7.2% vs. 4.3%), thrombocytopenia (12.0% vs. 2.9%), increased alanine aminotransferase (ALT) (6.4% vs. 0%), aspartate aminotransferase (AST) (16% vs. 2.9%), diarrhea (7.2% vs. 4.3%), weight loss (6.4% vs. 1.4%), fatigue (4.0% vs.1.4%), and rash (7.2% vs. 1.4%), as well as hypothyroidism (12.8% vs. 4.3%), compared to the targeted-immunotherapy group (Figure 4). This evidence concerns the gene GPT and hypothyroidism.